2022 Fiscal Year Research-status Report
Investigation of long non-coding RNA signatures of chemoresistance mesothelioma
Project/Area Number |
22K06980
|
Research Institution | Hiroshima University |
Principal Investigator |
AMATYA VISHWA・J 広島大学, 医系科学研究科(医), 講師 (90403625)
|
Co-Investigator(Kenkyū-buntansha) |
櫛谷 桂 広島大学, 医系科学研究科(医), 助教 (00508179)
武島 幸男 広島大学, 医系科学研究科(医), 教授 (70236462)
|
Project Period (FY) |
2022-04-01 – 2025-03-31
|
Keywords | Mesothelioma / Chemoresistant / lncRNA / Microarray |
Outline of Annual Research Achievements |
Malignant mesothelioma is the aggressive cancer. Cisplatin plus pemetrexed chemotherapy in mesothelioma patients has not improved the outcome, due to acquisition of chemoresistance by malignant mesothelioma, which is not yet fully known. Recently, long non-coding RNAs are reported to be involved in chemoresistance mechanism. However, the mechanism in mesothelioma cell is not yet clear. We analyzed gene expression of chemoresistant and chemosensitive mesothelioma using whole gene expression analysis. After Total RNA expression, the samples were hybridized in Genechip and data obtained from the genechip scanner was analyzed with transcriptome Analysis Consloe We found 2 fold differential expression of 209 noncoding gene between two groups, with 78 upregulated and 131 downregulated in chemoresistant mesothelioma. Further analysis is ungoing.
|
Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
The gene expression analysis cost more than expected. The experiments following the analysis of gene expression analysis needed extra expenditure. Thus, we have to wait a bit for next stage experiments.
|
Strategy for Future Research Activity |
Analysis of differentially expressed noncoding genes in mesothelioma cell lines using gene expression manipulation and its effect in chemotherapeutic agents.
|